Astellas Pharma (OTCMKTS:ALPMY) Stock Jumps 4.9% – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares traded up 4.9% during trading on Friday. The stock traded as high as $15.0525 and last traded at $15.0525. Approximately 85,696 shares traded hands during trading, a decline of 44% from the average daily volume of 152,989 shares. The stock had previously closed at $14.35.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The stock has a 50 day moving average of $14.77 and a 200 day moving average of $14.45. The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The firm has a market cap of $27.65 billion, a price-to-earnings ratio of 11.63 and a beta of 0.08.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.